Human IRAK3 Antibody

Detection of IRAK3 by Western Blot

IRAK3 isoform expression in primed macrophages. IRAK3 N-terminal to death domain (DD) (a.a. 1–14) is shaded grey, DD (15–104) is shaded blue, and pseudokinase domain (a.a. 171–446) is shaded green. (A) “Classical” full-length (CLS; NP_009130.2 a.a. 1–596). (B) “Alternative” IRAK-3 (ALT; NP_009130.2 a.a. 1–44, 105–596 of CLS) that lacks most of the DD. (C) Western blotting for IRAK3 in HEK293 cells (NIL) or HEK293 cells overexpressing classical or alternative IRAK3 blotted with two antibodies for IRAK3. (D) IRAK3 expression in monocyte-derived Mφ, unstimulated (NIL) or stimulated for 20 h with LPS, LPS/IFN gamma (M1), TNF, GM-CSF (GM), IL-4, or TGF-beta 1 (TGF); representative blots of two donors stained for IRAK3 (SAB3500193) and beta -actin (AC-74). Gene expression of (E) both IRAK3 isoforms and (F) the classical IRAK3 isoform in TNF-stimulated human Mφ. (G) Gene expression of Irak3 in LPS-stimulated (10 ng/mL) murine bone marrow-derived Mφ from wild-type or transgenic mice lacking either Tnfrsf1a or Tnfrsf1b; ANOVA for each respective knockout (KO) vs. wild type (WT), † p < 0.01, ‡ p < 0.001, n = 3–5 experiments. (H) Total IRAK3 gene expression in osteoarthritis (OA) and rheumatoid arthritis (RA) synovial explants and normal healthy monocytes (Mo), n = 12 OA, 19 RA, and 3 Mo. For (E, F, H) * p < 0.05, Student’s t-test. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40370470), licensed under a CC-BY license. Not internally tested by R&D Systems.